1. Introduction {#sec1}
===============

Gestational trophoblastic neoplasia (GTN) is a cancer that originates from placental tissue and exhibits the potential for invasion and widespread metastasis. GTN includes invasive moles, choriocarcinoma, placental site trophoblastic tumors, and epithelioid trophoblastic tumor, encompassing lesions that originate in the chorionic villi and the extravillous trophoblast; these lesions exhibit different degrees of proliferation, invasion, and dissemination \[[@B1], [@B2]\]. GTN generally spreads to the lungs, liver, central nervous system, and vagina. Accordingly, detection of metastasis is essential for evaluating disease progression \[[@B3]\]. GTN secretes human chorionic gonadotropin beta subunit (*β*-HCG), which serves as a useful biomarker, contributing to diagnosis, monitoring of therapeutic response, early detection of relapse, and assessment of cure \[[@B4], [@B5]\].

GTN is highly vascular, and biopsy is associated with a high risk of hemorrhage; thus, histological diagnosis is not necessary for treatment. However, chemotherapy is a highly effective, first-line treatment for GTN. Most women can be cured by chemotherapy without undergoing surgery, and surgery is often only performed when chemotherapy resistance is encountered. Tumors are often destroyed by chemotherapy and cannot be used for genetic research. Therefore, gene alterations of GTN have not been extensively studied.

With the development of precision medicine, liquid biopsy has emerged as a promising, noninvasive method for analysis of circulating tumor-derived material. Liquid biopsies, including tumor circulome, cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells, represent an innovative tool in precision oncology to overcome current limitations associated with tissue biopsies \[[@B6]\]. GTN has a rapid growth rate and is highly metastatic, showing early hematogenous spread. Thus, ctDNA sequencing may be a promising modality for genomic profiling and a viable tool for detecting more sensitive and specific biomarkers for clinical utility. ctDNA sequencing has been reported to have potential for disease monitoring, minimal residual disease detection, and therapeutic efficacy analysis in multiple different types of cancer \[[@B7]--[@B11]\]. However, few studies have reported cfDNA in gestational trophoblastic tumors.

Therefore, in this study, we investigated serum levels and gene alterations of targeted cfDNA in GTN, with the goal of elucidating the potential clinical and etiological roles of cfDNA in GTN.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Clinical Characteristics {#sec2.1}
------------------------------------------

Patients with GTN who met the inclusion criteria were enrolled in the Obstetrics and Gynecology Hospital of Fudan University from September 2017 to September 2018. Patients were included in the study according to the following criteria: diagnosed with GTN, according to the systematization of the diagnosis and GTN staging proposed by FIGO \[[@B12]\]; had not undergone chemotherapy; did not have any other tumorous disease or medical comorbidities; did not have any injury history or had not received any hormone therapy within 1 year prior to enrollment; and could be followed-up. Our project was approved by the Medical Ethics Committee of the Obstetrics and Gynecology Hospital of Fudan University, and all enrolled patients signed a consent form.

2.2. Reagents and Instruments {#sec2.2}
-----------------------------

Reagents included antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (cat. no. KC-5G4; Aksomics, Shanghai, China), antibone morphogenetic protein receptor type 1A (BMPR1A) antibody (cat. no. 12702-1-AP; Proteintech, IL, USA), antimitogen-activated protein kinase kinase kinase 1 (MAP3K1) antibody (cat. no. 19970-1-AP; Proteintech, IL, USA), Magnetic Serum/Plasma DNA Maxi Kit (Tiangen, Beijing, China), TRIzol reagent (Invitrogen, CA, USA), PrimeScript RT kit, and SYBR Premix Ex Taq II (Takara, Shiga, Japan). Instruments included an optical microscope, an inverted microscope and imaging system (Olympus, Tokyo, Japan), and an ABI 7900 real-time PCR system (Applied Biosystems, MA, USA).

2.3. Plasma Collection and Preparation {#sec2.3}
--------------------------------------

Ten milliliters of peripheral blood was collected in Cell Free DNA BCT before chemotherapy from patients with gestational trophoblastic tumors and then separated by centrifugation at 1600 ×*g* for 10 min at 4°C. The plasma layer was separated, and an additional centrifugation step at 16,000 ×*g* for 10 min was included. Plasma was stored at −80°C until analysis.

2.4. cfDNA Preparation {#sec2.4}
----------------------

cfDNA was prepared from 3 mL plasma according to the manufacturer\'s instructions using a Magnetic Serum/Plasma DNA Maxi Kit (Tiangen). cfDNA was quantified using an Agilent 2100 Bioanalyzer (Agilent, CA, USA). We used a targeted NGS panel (MyGenostics, Beijing, China) in this study, which included 559 genes reported to be associated with oncogenesis, progression, and targeted therapy (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). Whole exome sequencing of the 559 genes was performed to identify gene alterations in ctDNA from patients with GTN with a target region sequencing depth of more than 500x. DNA from paired peripheral blood mononuclear cells of the same patient was sequenced as the germline control.

2.5. Cell Culture {#sec2.5}
-----------------

The human choriocarcinoma cell lines JEG-3 and JAR were obtained from the cell bank at the Chinese Academy of Sciences (Shanghai, China). The human trophoblast cell line HTR8/sev8 was purchased from JENNICO Biological Technology (Guangzhou, China). These cell lines were obtained within 6 months before being used in this study and were authenticated by short tandem repeat validation analysis. HTR8/sev8 cells were cultured in 1640 complete medium, and JEG-3 and JAR cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM); both 1640 complete medium and DMEM complete medium were supplemented with 10% fetal bovine serum (Gibco, CA, USA), 100 IU/mL penicillin G, and 100 mg/mL streptomycin sulfate (Gibco).

2.6. Real-Time Quantitative Polymerase Chain Reaction (qPCR) {#sec2.6}
------------------------------------------------------------

Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer\'s instructions, followed by reverse transcription (RT) PCR using a PrimeScript RT kit (Takara) to generate cDNA. qPCR assay for multiple genes was then performed with SYBR Premix Ex Taq II (Takara) on an ABI 7900 real-time PCR system (Applied Biosystems). The *GAPDH* gene was used as a housekeeping gene. To ensure the qPCR quality, two or three primer pairs were designed for all amplification segments, but only one pair was used in the final test. Melting‐curve analyses were performed for all primers. To normalize cycle threshold (Ct) values obtained for each gene. All qPCR assays were repeated three times. The primers used for the detection of *BMPR1A*, *MAP3K1*, *HSP90AA1*, *ZNF217*, *RANBP2*, and *GAPDH* are described in [Table 1](#tab1){ref-type="table"}.

2.7. Western Blotting {#sec2.7}
---------------------

JEG-3, JAR, and HTR8/sev8 cells were lysed in sodium dodecyl sulfate (SDS) lysis buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1 mM phenylmethylsulfonylfluoride, and 1 mM Na~3~VO~4~). Equal amounts of total protein were separated by SDS-polyacrylamide gel electrophoresis and then transferred to polyvinylidene fluoride membranes (Merck Millipore, MA, USA). After blocking with 5% nonfat milk for 2 h, the membranes were incubated with primary antibodies at 4°C overnight, washed, and incubated with corresponding secondary antibodies at room temperature for 60 min. The protein bands of interest were visualized by fluorography using an enhanced chemiluminescence system (Pierce Protein Biology, IL, USA). BMPR1A and MAP3K1 expression levels were quantified and normalized to the expression of the loading control (GAPDH). Means ± standard deviations of triplicate experiments were plotted by GraphPad Prism software (version 8.0).

2.8. Statistical Analysis {#sec2.8}
-------------------------

Each experiment was repeated at least three times. Statistical analyses were performed using SPSS 23.0 (IBM Corporation, NY, USA) and Prism 8.0 (GraphPad Software, CA, USA). Data are presented as the means ± standard deviations. Statistical analyses were performed with Pearson analysis and Student\'s *t* tests, and results with *p* values of less than 0.05 were considered significant.

3. Results {#sec3}
==========

3.1. Clinical Features and cfDNA Concentrations {#sec3.1}
-----------------------------------------------

Eleven patients (aged 24--48 years, range: 34.1 ± 10.1 years) were enrolled in this study. Clinical characteristics are demonstrated in [Table 1](#tab1){ref-type="table"}. Among them, 9 of 11 patients had an antecedent molar pregnancy. Pathologic results of surgical specimens identified 4 cases of choriocarcinoma. According to the International Federation of Gynecology and Obstetrics (FIGO) prognosis scoring system, eight of the eleven GTN patients were low risk (8/11, 72.7%), and three were high risk (3/11, 27.3%). Among them, patients with low‐risk GTN (FIGO risk score 0--4) was treated with the single agent actinomycin D protocols. We reduced the threshold for the use of multiple agent chemotherapy in these patients with higher FIGO risk score (5-6) because of the increased risk of resistance to single agent chemotherapy. The cure rate of treatment was 100%, and all the patients\' *β*-HCG concentrations recovered to normal level within 4 months (77.7 ± 20.2 days).

We detected the cfDNA levels of all patients with GTN. The average cfDNA level was 0.43 ± 0.22 ng/*μ*L. The distribution of the maximum lesion diameter as well as the time for HCG recovery were checked using SPSS Statistics software (version 20). The Kolmogorov--Smirnov Sig. values both equaled 0.2, which was greater than 0.05; thus, the maximum lesion diameter and HCG recovery time were normally distributed. Pearson correlation analysis showed that there were correlations between the concentration of cfDNA and the maximum diameter of lesions (*r* = 0.6254, *p*=0.040; [Figure 1(a)](#fig1){ref-type="fig"}) and the time for *β*-HCG recovery to normal levels (*r* = 0.6095, *p*=0.047; [Figure 1(b)](#fig1){ref-type="fig"}). However, the distribution of *β*-HCG levels was not normal because the Kolmogorov--Smirnov Sig. value equaled 0.001 (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). The relationship between *β*-HCG levels and cfDNA concentrations was evaluated using Spearman\'s correlation analysis. The correlation between plasma *β*-HCG levels and cfDNA concentrations was low (*r* = −0.1545), and the *p* value indicated a lack of significance (*p*=0.654). Moreover, Student\'s *t*-tests showed that there were no significant correlations between the presence of lung metastasis and the concentration of cfDNA (*p*=0.90) or patient age (*p*=0.24; Figures [1(d)](#fig1){ref-type="fig"} & [1(e)](#fig1){ref-type="fig"}).

3.2. Gene Mutation Analysis Based on Next-Generation Sequencing (NGS) Panel Analysis of Clinically Relevant Mutations in cfDNA {#sec3.2}
------------------------------------------------------------------------------------------------------------------------------

ctDNA mutations were detected in all patients, and 73 mutant genes were detected in 11 patients. Eleven genes, including BMPR1A (3/11, 27.3%), low-density lipoprotein receptor-related protein 1B (LRP1B; 3/11, 27.3%), excision repair cross-complementing 4 (ERCC4; 2/11, 18.2%), fibroblast growth factor 14 (FGF14; 2/11, 18.2%), heat shock protein 90 alpha family class A member 1 (HSP90AA1; 2/11, 18.2%), lysine acetyltransferase 6A (KAT6A; 2/11, 18.2%), lysine methyltransferase 2D (KMT2D; 2/11, 18.2%), MAP3K1 (2/11, 18.2%), RAN binding protein 2 (RANBP2; 2/11, 18.2%), and Zinc finger protein 217 (ZNF217; 2/11, 18.2%), showed overlapping mutations ([Figure 2](#fig2){ref-type="fig"}, [Table 2](#tab2){ref-type="table"}).

3.3. Expression of Overlapping Mutations in Cell Lines {#sec3.3}
------------------------------------------------------

The mRNA levels of BMPR1A were decreased in human JAR and JEG-3 choriocarcinoma cells (*p* \< 0.0001), whereas the protein levels of BMPR1A were decreased slightly (*p* \> 0.05). MAP3K1 mRNA levels were increased in JAR and JEG-3 cell lines (*p*=0.0128, *p*=0.0012, respectively), and MAP3K1 protein levels were also upregulated significantly (*p*=0.0056, *p*=0.0006, respectively). The mRNA levels of *RANBP2* and *ZNF217* were higher in JAR cell lines than in HTR8 cells (*p*=0.0008, *p*=0.0026, respectively); however, there were no significant differences between JEG-3 and HTR8 cells. There were no significant differences in *HSP90AA1* mRNA expression among these three cell lines (Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

GTN mainly spreads by hematogenous dissemination. Therefore, in this study, we evaluated cfDNA, which provided complementary clinically relevant information for GTN. cfDNA consists of nucleic acids released from necrotic and apoptotic cells into blood circulation and is thought to be derived from both healthy and cancer cells \[[@B13]\]. cfDNA levels are higher in patients with cancer (0--1,000 mg/mL) than in healthy individuals (0--100 ng/mL). cfDNA analysis has been reported to have potential clinical utility in disease diagnosis and monitoring as well as early indicators of therapeutic efficacy in multiple cancer types \[[@B14]--[@B17]\]. However, few studies have investigated cfDNA in GTN. For example, Openshaw et al. reported that the presence of ctDNA was associated with serum hCG levels in women with GTN \[[@B18]\]. Additionally, in our study, we found that the maximum lesion diameter and the time for *β*-HCG recovery to normal levels were positively correlated with the levels of cfDNA in patients with GTN; thus, these factors may be used to reflect the tumor burden and evaluate the condition and prognosis of GTN, consistent with previous studies \[[@B19]--[@B21]\]. During tumorigenesis, apoptotic and necrotic tumor cells are engulfed by immune-related cells, such as monocytes and macrophages, thus releasing a large number of DNA fragments, which can increase the concentration of cfDNA. In addition, cfDNA levels may also increase because of the lysis of white blood cells, resulting in release of germline DNA.

We detected mutations in all pretreatment plasma samples in the 11 patients in this study, including 10 key overlapping mutant genes (*BMPR1A*, *LRP1B*, *ERCC4*, *FGF14*, *HSP90AA1*, *KAT6A*, *KMT2D*, *MAP3K1*, *RANBP2*, and *ZNF217*). These genes, particularly *MAP3K1* and *BMPR1A*, may be candidate genes in GTN initiation and progression, and could be targeted in the development of novel treatments for GTN. Sekiya et al. \[[@B22]\] examined the expression of nuclear factor-κB family proteins in normal placenta and choriocarcinoma cell lines; their results suggested that c-Rel may play a role in promoting the invasion of choriocarcinoma cells through phosphatidylinositol 3-kinase (PI3K)/AKT signaling. Additionally, Mello et al. \[[@B23]\] also revealed the involvement of phosphatase and tensin homolog (PTEN) and PI3K/Akt signaling pathways in patients with GTN. Gene ontology (GO) enrichment analysis provided support for positive regulation of several molecular functions, including regulation of DNA metabolic processes, regulation of hemopoiesis, and myeloid cell differentiation. Moreover, pathway enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database suggested the potential involvement of the PI3K/AKT signaling pathway, hepatocellular carcinoma, signaling pathways regulating pluripotency of stem cells, and extracellular signal-regulated kinase (ERK) 1 and ERK2 cascades.

Among the 11 patients with GTN evaluated in this study, *BMPR1A* mutations were detected in three patients (c.1001 T \> C:p.L334S; 3/11, 27.3%). Interestingly, all three patients had lung metastases. Diseases associated with the protein coding gene *BMPR1A* include juvenile polyposis syndrome and polyposis syndrome \[[@B24]\], and this gene has been shown to be related to the mammalian target of rapamycin (mTOR) and PI3K/AKT signaling pathways \[[@B25]\]. Low expression of *BMPR1A* also blocks the progression and metastasis of breast cancer \[[@B26]\], and BMPR1A may play a role in promoting the metastasis of GTN. GTN mainly spreads by hematogenous dissemination, with the lungs being the most common distant organ for GTN metastasis. According to GO enrichment analysis, regulation of hemopoiesis could play a role in the oncogenesis of GTN. Thus, tumor cells escape from the primary site and migrate into the circulatory system, and hematopoietic cells or cytokines may infiltrate tumor sites and generate a favorable microenvironment for tumor metastasis \[[@B27], [@B28]\]. Finally, the metastatic cells proliferate and form micrometastases or macrometastases.

Overall, our study demonstrated, for the first time, that cfDNA levels could have potential value in the assessment value in disease severity of GTN and that ctDNA sequencing may be a promising approach for identifying gene alterations in GTN. In the future, additional studies with more samples are needed to further explore the value of cfDNA sequencing in patients with GTN.
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###### 

Supplementary Table 1. A targeted NGS panel including 559 genes. Supplementary Table 2. Normal distribution test for plasma HCG level.

###### 

Click here for additional data file.

![Relativity of clinical characteristics and the concentration of cfDNA. (a) Correlation of maximum lesion diameter and the concentration of cfDNA; (b) correlation of the time for *β*-HCG recovering to normal level and the concentration of cfDNA; (c) correlation of plasma HCG level and cfDNA concentration; (d) correlation of distant metastasis and cfDNA concentration (*p*=0.90); (e) correlation of age and cfDNA concentration (*p*=0.24).](BMRI2020-1314967.001){#fig1}

![ctDNA sequencing results of GTN patients.](BMRI2020-1314967.002){#fig2}

![mRNA expression of mutations in cell lines (^*∗*^*p* \< 0.05, ^*∗∗*^*p* \< 0.001).](BMRI2020-1314967.003){#fig3}

![Protein expression of BMPR1A and MAP3K1 in three cell lines. (a) Western blotting gel image for BMPR1A and MAP3K1, and GAPDH was used as loading control. (b) Values of mean ± S.D. of triplicate experiments were plotted (^*∗*^*p* \< 0.05, ^*∗∗*^*p* \< 0.001).](BMRI2020-1314967.004){#fig4}

###### 

Clinical characteristics of the 11 GTN patients.

  Patients   Age   Antecedent pregnancy   Interval from index pregnancy (months)   Distant metastasis (number)   Maximum lesion diameter (cm)   Plasma HCG level (U/L)   Chemotherapy regimens^∗^   Surgery^\#^               Pathologic results   Diagnosis   Time for *β*-HCG recovering to normal level (days)   cfDNA concentration (ng/*μ*L)
  ---------- ----- ---------------------- ---------------------------------------- ----------------------------- ------------------------------ ------------------------ -------------------------- ------------------------- -------------------- ----------- ---------------------------------------------------- -------------------------------
  P1         48    Mole                   1                                        Lung (6)                      3.0                            33740                    EMA‐CO                     TLH                       Invasive mole        GTN III:6   63                                                   0.181
  P2         52    Mole                   1                                        Lung (6)                      6.6                            \>272600                 EMA‐CO                     TLH and BSO               Invasive mole        GTN III:9   112                                                  0.928
  P3         40    Mole                   \>12                                     No                            8.2                            1622                     EMA‐CO                     Uterine wedge resection   Choriocarcinoma      GTN I:8     80                                                   0.522
  P4         25    Mole                   4                                        No                            3.0                            4209                     Actinomycin D              Uterine wedge resection   Choriocarcinoma      GTN I:3     63                                                   0.477
  P5         34    Mole                   3                                        No                            3.1                            170672                   EMA‐CO                     No                        None                 GTN I:5     60                                                   0.28
  P6         26    Mole                   1                                        Lung (1)                      7.0                            5036                     Actinomycin D              No                        None                 GTN III:4   76                                                   0.596
  P7         25    Mole                   1                                        Lung (7)                      4.2                            12730                    EMA‐CO                     No                        None                 GTN III:5   69                                                   0.199
  P8         24    Mole                   1                                        Lung (2)                      3.9                            12498                    EMA‐CO                     No                        None                 GTN III:4   89                                                   0.419
  P9         43    Abortion               3                                        No                            5.0                            121750                   EMA‐CO                     TLH                       Choriocarcinoma      GTN I:8     111                                                  0.517
  P10        30    Abortion               2                                        Lung (4)                      4.2                            18030                    EMA‐CO                     D&C                       Choriocarcinoma      GTN III:5   83                                                   0.211
  P11        28    Mole                   4                                        No                            6.1                            15957                    EMA‐CO                     Uterine wedge resection   Invasive mole        GTN I:5     49                                                   0.403

^∗^EMA‐CO: etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine. ^\#^TLH: total laparoscopic hysterectomy; BSO: bilateral salphingo-oophorectomy; D&C: dilatation and curettage.

###### 

Details of overlapping mutations.

  No.         Gene       Transcript        Patients            Exons       Nucleotide variation   Type
  ----------- ---------- ----------------- ------------------- ----------- ---------------------- -----------
  1           BMPR1A     NM_004329         P1                  Exon10      c.1001 T \> C          SNV
  P2          Exon10     c.1001 T \> C     SNV                                                    
  P8          Exon10     c.1001 T \> C     SNV                                                    
  2           LRP1B      NM_018557         P1                  Exon39      c.6221 A \> C          SNV
  P9          Exon43     c.7034 T \> G     SNV                                                    
  P10         Exon39     c.6221 A \> C     SNV                                                    
  3           ERCC4      NM_005236         P4                  Exon9       c.1853 T \> A          SNV
  P10         Exon2      c.304 A \> T      SNV                                                    
  4           FGF14      NM_001321937      P1                  Exon4       c.424-3delT            Splicing
  P3          Exon4      c.424-3delT       Splicing                                               
  5           HSP90AA1   NM_005348         P2                  Exon5       c.836_838delAGA        Deletion
  P3          Exon5      c.836_838delAGA   Deletion                                               
  6           KAT6A      NM_006766         P1                  Exon2       c.282 A \> T           SNV
  NM_006766   P2         Exon16            c.3218_3219insGGA   Insertion                          
  7           KMT2D      NM_003482         P2                  Exon13      c.4059_4061delGGA      Deletion
  NM_003482   P5         Exon10            c.1301 T \> G       SNV                                
  8           MAP3K1     NM_005921         P1                  Exon14      c.2917_2918insCTC      Insertion
  P3          Exon20     c.4487delG        Deletion                                               
  9           RANBP2     NM_006267         P5                  Exon16      c.2275 G \> A          SNV
  P8          Exon20     c.6680 A \> G     SNV                                                    
  10          ZNF217     NM_006526         P1                  Exon3       c.1645 G \> A          SNV
  P10         Exon3      c.1645 G \> A     SNV                                                    
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